Table 2.
Medical history and health status of study participants (n = 2200).
| Status | All Participants (n = 2200) |
Vaccinated participants (n = 1929) |
Unvaccinated participants (n = 271) |
X2 | p-value |
|---|---|---|---|---|---|
| Food or medicine allergic history | |||||
| Yes | 250 (11.4%) | 199 (10.3%) | 51 (18.8%) | 17.057 | < 0.001 |
| No | 1950 (88.6%) | 1730 (89.7%) | 220 (81.2%) | ||
| Vaccine allergic history | |||||
| Yes | 82 (3.7%) | 59 (3.1%) | 23 (8.5%) | 19.514 | < 0.001 |
| No | 2118 (96.3%) | 1870 (96.9%) | 248 (91.5%) | ||
| Smoking history | |||||
| Yes | 745 (33.9%) | 656 (34.0%) | 89 (32.8%) | 0.144 | 0.704 |
| No | 1455 (66.1%) | 1273 (66.0%) | 182 (67.2%) | ||
| Alcohol intake history | |||||
| Yes | 688 (31.3%) | 623 (32.3%) | 65 (24.0%) | 7.637 | 0.006 |
| No | 1512 (68.7%) | 1306 (67.7%) | 206 (76.0%) | ||
| Diabetic family history | |||||
| Yes | 890 (40.5%) | 780 (40.4%) | 110 (40.6%) | 0.092 | 0.955 |
| No | 1053 (47.9%) | 925 (48.0%) | 128 (47.2%) | ||
| Uncertain | 257 (11.7%) | 224 (11.6%) | 33 (12.2%) | ||
| Self–reported BMI, kg/m2 | |||||
| < 18.5 | 93 (4.2%) | 72 (3.7%) | 21 (7.7%) | 12.401 | 0.006 |
| 18.5-23.9 | 910 (41.4%) | 794 (41.1%) | 116 (42.8%) | ||
| 24.0-27.9 | 759 (34.5%) | 670 (34.7%) | 89 (32.8%) | ||
| ≥ 28 | 438 (19.9%) | 393 (20.4%) | 45 (16.6%) | ||
| Type of diabetes | |||||
| Type 1 | 232 (10.6%) | 197 (10.2%) | 35 (12.9%) | 6.189 | 0.103 |
| Type 2 | 1873 (85.1%) | 1650 (85.5%) | 223 (82.3%) | ||
| Unclassified diabetes | 77 (3.5%) | 69 (3.6%) | 8 (3.0%) | ||
| Others | 18 (0.8%) | 13 (0.7%) | 5 (1.8%) | ||
| Chronic disease | |||||
| Hypertension | 824 (37.5%) | 701 (36.3%) | 123 (45.4%) | 102.818 | < 0.001 |
| Hyperlipidemia | 817 (37.1%) | 708 (36.7%) | 109 (40.2%) | ||
| Metabolic syndrome | 115 (5.2%) | 99 (5.1%) | 16 (5.9%) | ||
| Chronic respiratory disease | 74 (3.4%) | 63 (3.3%) | 11 (4.1%) | ||
| Cardiovascular and cerebrovascular diseases | 258 (11.7%) | 198 (10.3%) | 60 (22.1%) | ||
| Liver or kidney diseases | 57 (2.6%) | 43 (2.2%) | 14 (5.2%) | ||
| Inflammatory immune diseases | 39 (1.8%) | 22 (1.1%) | 17 (6.3%) | ||
| Cancer | 50 (2.3%) | 30 (1.6%) | 20 (7.4%) | ||
| Others | 128 (5.8%) | 100 (5.2%) | 28 (10.3%) | ||
| No | 807 (36.7%) | 739 (38.3%) | 68 (25.1%) | ||
| Diabetes complications | |||||
| Diabetic eye disease | 280 (12.7%) | 233 (12.1%) | 57 (21.0%) | 71.693 | < 0.001 |
| Diabetic Nephropathy | 177 (8.1%) | 129 (6.6%) | 49 (18.1%) | ||
| Diabetic foot | 65 (3.0%) | 45 (2.3%) | 20 (7.4%) | ||
| Diabetic neuropathy | 290 (13.2%) | 235 (12.2%) | 54 (19.9%) | ||
| No | 1652 (75.1%) | 1479 (76.7%) | 172 (63.5%) | ||
| Time since diabetes diagnosis, years | |||||
| ≤1 | 499 (22.7%) | 456 (23.6%) | 43 (15.9%) | 15.38 | < 0.001 |
| 1–10 | 889 (40.4%) | 788 (40.9%) | 101 (37.3%) | ||
| ≧10 | 812 (36.9%) | 685 (35.5%) | 127 (46.9%) | ||
p-value is from the Chi-square test.
Bold values show significant differences (P< 0.05).
a
This was a multiple-choice question.